DocGo (DCGO) Expected to Announce Quarterly Earnings on Monday

DocGo (NASDAQ:DCGO) is anticipated to post its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect DocGo to post earnings of ($0.02) per share and revenue of $72.4760 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 5:00 PM ET.

DocGo Trading Down 0.5%

NASDAQ:DCGO traded down $0.00 on Monday, reaching $0.67. 154,789 shares of the stock traded hands, compared to its average volume of 958,117. The firm has a market capitalization of $66.26 million, a price-to-earnings ratio of -0.36 and a beta of 1.02. The company’s 50 day moving average is $0.65 and its 200-day moving average is $0.84. DocGo has a 1-year low of $0.49 and a 1-year high of $2.45.

Hedge Funds Weigh In On DocGo

Large investors have recently modified their holdings of the company. Cerity Partners LLC bought a new position in shares of DocGo in the 2nd quarter worth $37,000. Strs Ohio bought a new position in shares of DocGo in the 1st quarter worth $76,000. Engineers Gate Manager LP bought a new position in shares of DocGo in the 2nd quarter worth $52,000. Neuberger Berman Group LLC bought a new position in shares of DocGo in the 4th quarter worth $29,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of DocGo in the 4th quarter worth $40,000. 56.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DCGO shares. Needham & Company LLC reissued a “buy” rating and set a $3.00 target price on shares of DocGo in a research report on Tuesday, March 17th. Cantor Fitzgerald restated an “overweight” rating and set a $3.00 price target on shares of DocGo in a report on Tuesday, March 17th. Stifel Nicolaus cut their price target on DocGo from $4.00 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Finally, Canaccord Genuity Group cut their price target on DocGo from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 25th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $2.38.

DocGo Company Profile

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.